Press Releases

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Emmes Appoints Peter Ronco as Chief Executive Officer

Bora merges with Sunway Biotech to launch global Nutraceuticals offering

Nostics Appoints Medtech Leader Jeroen Nieuwenhuis as CEO

Nostics, a medical diagnostics startup, is thrilled to announce the appointment of veteran medtech entrepreneur, Jeroen Nieuwenhuis, as its new Chief Executive Officer. As the company prepares to introduce its revolutionary diagnostics technology to the point-of-care market, Jeroen's inclusion marks an important milestone in Nostics’ journey.

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth Funding enables Mural Health to expand its Mural Link platform to modernize the clinical trial participant experience

Experts from CD Formulation Share Insights on How to Prepare Nano-vesicles for Encapsulating Protein Drugs

Biofourmis Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution

Biofourmis Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution

Alfa Chemistry Unveils Revitalized Strong/Weak Acid Cation Resin and Base Anion Resin Lineup

BioIVT Webinar Will Discuss How to Manage Uncooperative Drugs in In Vitro Transporter Research

This webinar will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.

uMed Partners with The Michael J. Fox Foundation to Support Wide-scale Study Exploring Link Between Smell Loss and Parkinson’s

Health and research tech company uMed is partnering with the Michael J. Fox foundation to run a smell test study to investigate the link between loss of smell and Parkinson’s disease. uMed’s technology and consumer-based marketing techniques will help the Michael J. Fox Foundation overcome traditional barriers to engaging clinical trial volunteers and reach a large, diverse patient cohort to accelerate the pace of research and access to potential breakthroughs.

Ann Graham, Founder of MIB Agents, Joins NCCN Guidelines Panel

Ann Graham, Founder and Executive Director of MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to making it better for its community of patients, caregivers, doctors, and researchers, has officially joined the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Bone Cancer, in the role of patient advocate.

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

Daptomycin ReadyMade™ Solution to Power Up Spectrum and Microbiology Applications

CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems

Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

Kindeva Drug Delivery Appoints Brian Schubmehl as Chief Human Resources Officer

Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that Brian Schubmehl has joined the company as Chief Human Resources Officer.

Huateng Pharma to Attend CPHI Barcelona 2023

Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.